Market revenue in 2023 | USD 159.4 million |
Market revenue in 2030 | USD 480.6 million |
Growth rate | 17.1% (CAGR from 2023 to 2030) |
Largest segment | Instruments |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Consumables, Instruments, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Agilent Technologies Inc, Illumina Inc, Qiagen NV, Roche Holding AG, Macrogenics Inc, PerkinElmer, Pacific Biosciences of California Inc, BGI Group, BGC Group Inc Ordinary Shares Class A, Bio-Rad Laboratories Inc, Myriad Genetics Inc, PierianDx, Eurofins Scientific SE |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dna sequencing market will help companies and investors design strategic landscapes.
Instruments was the largest segment with a revenue share of 49.69% in 2023. Horizon Databook has segmented the Australia dna sequencing market based on consumables, instruments, services covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of well-established healthcare infrastructure & research facilities, favorable reimbursement policies, and availability of world-class researchers are anticipated to be major factors boosting the market in Australia.
In December 2020, the Victorian government partnered with Illumina & the University of Melbourne to obtain USD 60 million in funding and establish the Illumina–University of Melbourne Genomics Hub. In September 2020, Australia-based Communicable Disease Genomics Network and U.S.-based Illumina collaborated to trace COVID-19 using the latter’s next-generation genomic sequencing technology.
Furthermore, the high prevalence of chronic & infectious diseases, such as cancer & HIV, is propelling the demand for efficient NGS solutions in the country for diagnostic purposes. Thus, leading and emerging players in the market are involved in gaining approvals to introduce novel NGS-based tests in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia dna sequencing market , including forecasts for subscribers. This country databook contains high-level insights into Australia dna sequencing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account